Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNML54
|
|||
| Drug Name |
Lumoxiti
|
|||
| Synonyms |
Moxetumumab pasudotox-tdfk
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hairy cell leukaemia [ICD-11: 2A82.2; ICD-10: C91.4; ICD-9: 202.4] | Phase 1 | [1] | |
| Company |
Innate Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell receptor CD22 (CD22) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | B Cell Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03805932) Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Innate Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.